このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

びらん性炎症性手の変形性関節症におけるメトトレキサート (MERINO)

2026年10月30日 更新者:Ida Kristin Haugen、Diakonhjemmet Hospital

びらん性炎症性変形性関節症におけるメトトレキサート(MERINO)試験:びらん性炎症性手の変形性関節症におけるメトトレキサートの臨床的有効性と安全性を調査するための無作為化プラセボ対照試験。

A placebo-controlled randomized controlled trial exploring the effect of methotrexate on pain, function and structural outcomes in erosive inflammatory hand osteoarthritis.

調査の概要

状態

積極的、募集していない

条件

介入・治療

詳細な説明

The trial will include Norwegian adult males and females with symptomatic erosive inflammatory hand osteoarthritis.

Participants will be randomized 1:1 to either:

  1. Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg the remaining weeks (intervention group). Dosage can be reduced to as low as 10 mg if higher doses are not tolerated.
  2. Placebo (control group).

Both arms will receive folic acid 1mg daily.

The treatment duration for both groups is 52 weeks.

研究の種類

介入

入学 (推定)

163

段階

  • フェーズ 4

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Finger joint pain 40-80 on 0-100 visual analog scale (VAS) with insufficient pain relief from, inability to tolerate or contra-indications to oral paracetamol and/or NSAIDs, and hand symptoms (pain, aching, or stiffness) on most days the previous 6 weeks before randomization.
  • Hand OA according to the American College of Rheumatology (ACR) criteria, at least 1 distal (DIP) or proximal interphalangeal (PIP) joint of the 2nd-5th finger with radiographic pre-erosive (J-phase) or erosive disease (E-phase) according to the Verbruggen-Veys anatomical phase system, and at least two DIP/PIP joints with power Doppler signal of at least grade 1 or grey-scale synovitis of at least grade 2 on ultrasound.

Exclusion Criteria:

A full list of the exclusion criteria for this study comprised the following:

  • Contraindications to methotrexate:

    • Abnormal renal function, defined as serum creatinine >142 µmol/L in women and >168 µmol/L in men, or a glomeruli filtration rate (GFR) <40 mL/min/1.73 m2.
    • Abnormal liver function, defined as transaminases above the upper normal limit, active or previous hepatitis B or C infection, or known cirrhosis
    • Lung fibrosis (maximum 6 months old x-ray), active infection, or reduced hematopoiesis (i.e. anemia, leukopenia and/or thrombocytopenia).
    • Planned pregnancy within 18 months after screening (men/women), and pregnancy, breastfeeding, or insufficient anti-conception therapy for female fertile participants. Contraception should be maintained during treatment and until the end of systemic exposure, i.e. 3 months after methotrexate discontinuation. Sufficient anti-conception therapy consists of intra-uterine device (coil) or hormonal anti-conception (birth control pills, implant, intra-uterine system, dermal patch, vaginal ring, or injections).
    • Alcohol or other drug abuse in the last year.
    • Intolerance to lactose.
  • Chronic inflammatory rheumatic diseases (such as rheumatoid arthritis and psoriatic arthritis or gout), active inflammatory bowel disease, or positive rheumatoid factor or anti-CCP antibodies.

  • Other severe co-morbidities such as hemochromatosis, fibromyalgia, psoriasis, blood dyscrasias, and coagulation disorders, history of malignancy (except successfully treated squamous or basal cell skin carcinoma), uncontrolled diabetes mellitus, severe hypertension, unstable ischemic heart disease, severe heart failure, severe pulmonary disease, severe and/or opportunistic infections and/or chronic infections, active tuberculosis, positive human immunodeficiency virus (HIV) status, recent stroke, bone marrow hypoplasia, or demyelinating diseases of the central nervous system.

  • Other likely causes of hand symptoms: thoracic outlet syndrome, carpal tunnel disease, diabetic cheiropathy, injury in finger joints previous 6 months, or palmar tenosynovitis/trigger finger.

  • Oral or intra-muscular steroids in the previous month

  • Intra-articular treatments or aspirations of any kind of any joint in the hands 3 months before inclusion

  • Analgesics or NSAIDs, unless stable dosage for ≥1 month.

  • Symptomatic slow-acting drugs for OA (SYSADOA), unless stable dose for ≥3 months and require stable dose throughout the study.

  • Disease-modifying osteoarthritis drugs (DMOADs) previous three months.

  • Scheduled hand surgery during study participation.

  • Planning to start other treatments for hand OA in the study participation period.

  • Not able to adhere to the study visit schedule and protocol requirements.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Methotrexate

Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg the remaining weeks.

Additional Folic acid 1mg prescribed daily.

Methotrexate 2.5mg oral tablet.

Folic acid

プラセボコンパレーター:Placebo

3 capsules per week for two weeks, followed by 4 capsules the remaining weeks.

Additional Folic acid 1mg prescribed daily.

Placebo capsule

Folic acid

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Finger pain on a visual analogue scale
時間枠:6 months

Difference in self-reported finger joint pain previous 48 hours on a 0-100 mm scale at 6 months of treatment; higher value indicate worse outcome.

6 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Finger pain on a visual analogue scale
時間枠:Month 1, 3, 9 and 12.

Self-reported finger pain previous 48 hours on a 0-100 mm scale; higher value indicate worse outcome.

Month 1, 3, 9 and 12.
Thumb pain on a visual analogue scale
時間枠:Month 1, 3, 6, 9 and 12.

Self-reported thumb pain previous 48 hours on a 0-100 mm scale; higher value indicate worse outcome.

Month 1, 3, 6, 9 and 12.
Pain most painful finger joint on a visual analogue scale
時間枠:Month 1, 3, 6, 9 and 12.

Pain most painful finger joint last 48 hours on a 0-100 mm scale; higher value indicate worse outcome.

Month 1, 3, 6, 9 and 12.
Patient-reported disease activity on a visual analogue scale
時間枠:Month 1, 3, 6, 9 and 12.

Patient-reported disease activity last 48 hours on a 0-100 mm scale; higher value indicate worse outcome.

Month 1, 3, 6, 9 and 12.
Pain all joints on a visual analogue scale
時間枠:Month 1, 3, 6, 9 and 12.

Pain all joints last 48 hours on a 0-100 mm scale; higher value indicate worse outcome.

Month 1, 3, 6, 9 and 12.
Hand diagram pain
時間枠:Month 6.

Finger pain and thumb base pain (yes/no) on hand diagram

Month 6.
Body diagram pain
時間枠:Month 6.

Pain in other joints (yes/no) on body diagram

Month 6.
AUSCAN
時間枠:Month 1, 3, 6, 9 and 12.

Australian/Canadian hand index (AUSCAN), sum score 0-60, higher value indicate worse outcome.

Month 1, 3, 6, 9 and 12.
OMERACT-OARSI responder criteria
時間枠:Month 1, 3, 6, 9 and 12.

Fulfillment of Outcome Measures in Rheumatology Osteoarthritis Research Society International (OMERACT-OARSI) responder criteria.

Month 1, 3, 6, 9 and 12.
EQ-5D
時間枠:Month 1, 3, 6, 9 and 12.

Quality-adjusted life years (QALYs) based on the health-related utility scores measured by the generic instrument EuroQol 5 dimensions (EQ-5D), sum score 5-35, higher value indicate worse outcome, in addition to a 0-100 visual analogue scale where higher value indicate better outcome.

Month 1, 3, 6, 9 and 12.
MHOQ
時間枠:Month 6.

Michigan Hand Outcomes Questionnaire (MHOQ) pain and physical function subscales; function subscale range 10-50, higher value indicate worse outcome; task subscale range 17-85, higher value indicate worse outcome; work subscale range 5-25, higher value indicate worse outcome; pain subscale range 10-48, higher value indicate better outcome.

Month 6.
Grip strength
時間枠:Month 1, 3, 6, 9 and 12.

Grip strength (in kg; using a hand dynamometer)

Month 1, 3, 6, 9 and 12.
HOOS-12
時間枠:Month 6.

Hip disability and Osteoarthritis Outcome Score (HOOS)-12, range 12-60, higher value indicate worse outcome.

Month 6.
KOOS-12
時間枠:Month 6.

Knee injury and Osteoarthritis Outcome Score (KOOS)-12, range 12-60, higher value indicate worse outcome.

Month 6.
Concomitant medication
時間枠:Month 1, 3, 6, 9 and 12.

Concomitant medication

Month 1, 3, 6, 9 and 12.
Tender and swollen joints
時間枠:Month 1, 3, 6, 9 and 12.

Number of tender and swollen joints (range 0-30), higher values indicate more affected joints.

Month 1, 3, 6, 9 and 12.
Physician-reported disease activity on a visual analogue scale
時間枠:Month 1, 3, 6, 9 and 12.

Patient-reported disease activity on a 0-100 mm scale; higher value indicate worse outcome.

Month 1, 3, 6, 9 and 12.
Hand radiographs: Kellgren Lawrence
時間枠:Month 6 and 12

Conventional radiographs: change in radiographic severity according to Kellgren-Lawrence scale, range 0-4 in each joint higher value indicate worse outcome.

Month 6 and 12
Hand radiographs: Verbruggen-Veys anatomical phase scoring system
時間枠:Month 6 and 12

Conventional radiographs: radiographic severity in finger joints according to Verbruggen-Veys anatomical phase scoring system, range 1-5; higher value indicate worse outcome.

Month 6 and 12
Hand radiographs: OARSI atlas
時間枠:Month 6 and 12

Conventional radiographs: rdiographic severity according to the Osteoarthritis Research Society International (OARSI) atlas for the presence/severity of osteophytes, joint space narrowing and erosions.

Month 6 and 12
Hand MRI
時間枠:Month 6

MRI of dominant hand: number of joints with synovitis and BMLs

Month 6
Hand ultrasound
時間枠:Month 1, 3, 6, 9 and 12.

Ultrasound: number of finger joints with synovial thickening and power Doppler signals.

Month 1, 3, 6, 9 and 12.
Knee ultrasound
時間枠:Month 6

Ultrasound: degree of synovitis in knee joints

Month 6
Hip ultrasound
時間枠:Month 6

Ultrasound: degree of synovitis in hip joints

Month 6
Adverse events
時間枠:Through study completion, maximum 12 months, in addition to 3 months after end of treatment.

Number of adverse events, serious adverse events, and withdrawals because of adverse events.

Through study completion, maximum 12 months, in addition to 3 months after end of treatment.

その他の成果指標

結果測定
メジャーの説明
時間枠
Sub-study: biopsy of knee OA
時間枠:Month 6

Change in synovial cellular composition and gene expression with single-cell RNA sequencing analyses; subgroup analyses, n=16 patients

Month 6
Sub-study: knee pain on a visual analogue scale
時間枠:Month 6

Self-reported knee pain previous 48 hours on a 0-100 mm scale at 6 months of treatment; higher value indicate worse outcome.

Month 6
Question about blinding
時間枠:Month 12

The participants are asked which treatment they think they have received

Month 12
HADS
時間枠:Month 6

Hospital Anxiety and Depression Scales (HADS), range 0-42, higher value indicate worse outcome.

Month 6
PCS
時間枠:Month 6

Pain catastrophizing scale, range 0-12, higher value indicate worse outcome.

Month 6
PSQ
時間枠:Month 6

Pain Sensitivity Questionnaire (PSQ), range 0-170, higher value indicate worse outcome.

Month 6
Anchor questions for MCII and PASS
時間枠:Month 6

Questions about perceived improvement and acceptable symptom state that will be used to define minimally clinically important improvement and patient acceptable symptom state for other questionnaires

Month 6
ASES
時間枠:Month 6

Arthritis Self Efficacy Scale (ASES), range 10-100, higher value indicate better outcome.

Month 6
Pain sensitization
時間枠:Month 6

Pain sensitization: Pressure Pain Thresholds (PPT) by digital algometer; temporal summation by punctate probes; Conditioned Pain Modulation (CPM) by blood pressure ischemic test.

Month 6
Soluble biomarkers of extracellular matrix turnover
時間枠:Month 6 and 12

Markers of collagen degradation (s-COMP, s-C1M, s-C2M, s-C3M, s-CTX1, sHA), collagen synthesis (s-proC2), aggrecan degradation (s-huARGS) and inflammation (s-calprotectin, s- vimentin, s-hsCRP and s-CRPM); Inflammatory cytokines (IL-1β, IL-1ra, IL-4, IL-6, IL-10, IL-12, IL-17, IL-18, IL-21, IFN-γ, TNF-α, VEGF, GM-CSF, CCL2, CCL3, CCL4, CXCL10) and hormones (leptin and resistin).

Month 6 and 12
Omics
時間枠:Month 6 and 12

Omics analyses of whole blood

Month 6 and 12

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • スタディチェア:Tore K Kvien, MD, PhD、Professor Em.

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年8月12日

一次修了 (実際)

2026年9月2日

研究の完了 (推定)

2026年12月1日

試験登録日

最初に提出

2020年9月22日

QC基準を満たした最初の提出物

2020年10月1日

最初の投稿 (実際)

2020年10月8日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月3日

QC基準を満たした最後の更新が送信されました

2026年10月30日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • DIA2020-01

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

The trialists and other study personnel that conceive of the study, and then plan, manage, monitor, analyze and publish it, will have access to IPD. Participants' identification code numbers are de-identified by replacing the original code number with a new random code number. Only the PI and project coordinator have access to this code.

The protocol, SAP, ICF, and CSR will be shared with regulatory agents as required.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。